Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

DelveInsight's "ENTYVIO Market Size, Forecast, and Market Insight Report" highlights the details around ENTYVIO, a gut-selective ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares. AI is about to change ...

Meeting to be held in Boston on April 9 and in New York on April 10 hosted by Piper Sandler.Stay Ahead of the Market: Discover outperforming ...

On Friday, H.C. Wainwright’s analysts reaffirmed a Buy rating on Altimmune (NASDAQ:ALT) shares, with a steady price target of $12.00. According to InvestingPro data, the stock is currently trading ...

On Friday, H.C. Wainwright’s analysts reaffirmed a Buy rating on Altimmune (NASDAQ:ALT) shares, with a steady price target of $12.00. According to InvestingPro data, the stock is currently ...

In the last three months, 8 analysts have published ratings on Altimmune (NASDAQ:ALT), offering a diverse range of perspectives from bullish to bearish. The table below provides a concise overview ...